Näiden koulutusten sisältö on Novo Nordiskista riippumattoman sisällöntuottajan tuottamaa. Osa koulutuksista on EACCME-akkreditoituja, joten niitä voidaan lukea hyväksi joidenkin erikoisalojen erikoistumisopinnoissa ja diabeteksen erityispätevyyttä suoritettaessa. Pisteiden kelpoisuus täytyy kuitenkin varmistaa kolutuksesta vastaavalta taholta. Novo Nordisk ei vastaa koulutusten sisällöstä. Osa koulutusten järjestäjistä vaatii luomaan erilliset tunnukset omalle sivustolleen.
This course is developed by Medscape Education Global. Medscape is one of the leading digital platforms for medical education. A comprehensive array of innovative formats, in multiple languages, insures the right educational solution is available to best achieve desired objectives—from text-based articles to state-of-the-art multimedia formats and the most sophisticated simulation environments. Activity formats include Clinical Insights, Expert Perspective, Instructional Series Programming, Next-Generation Symposia, Patient-Case Approaches, including Simulation and Clinical Advances.
Data from recent clinical and cardiovascular outcomes trials (CVOTs) suggest that glucagonlike peptide-1 (GLP-1) receptor agonists have multi-factorial benefits beyond glycaemic control.
On this programme, you'll find a collection of dynamic, interactive educational courses addressing the latest evidence for managing individuals with diabetes and other disordes - especially established or risk factors for atheroscletoric cardiovascular disease (ASCVD) and chronic kidney disease (CKD)
Made for: Specialists, Primary Care Physicians
Disease areas: Diabetes, Cardiovascular Disease, Chronic Kidney Disease
Developed by: Medscape Education Global
